Evidence map›Paper›PMID 30467676›Full record

ArticleJournal of natural medicines2019

Sakuranetin downregulates inducible nitric oxide synthase expression by affecting interleukin-1 receptor and CCAAT/enhancer-binding protein β.

Yuko Yamauchi, Tetsuya Okuyama, Toshinari Ishii, Tadayoshi Okumura, Yukinobu Ikeya, Mikio Nishizawa

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Identification of Anti-Inflammatory Compounds fromMolecules (Basel, Switzerland) · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Molecules (Basel, Switzerland) · 2021
    Review
  9. Review
  10. Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yuko YamauchiDepartment of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.
Tetsuya OkuyamaDepartment of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.
Toshinari IshiiDepartment of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.
Tadayoshi OkumuraResearch Organization of Science and Technology, Ritsumeikan University, Kusatsu, Shiga, Japan.
Yukinobu IkeyaCenter for Supporting Pharmaceutical Education, Daiichi University of Pharmacy, 22-1 Tamagawa-cho, Minami-ku, Fukuoka, 815-8511, Japan. y-ikeya@daiichi-cps.ac.jp.ORCID http://orcid.org/0000-0003-2383-4801
Mikio NishizawaDepartment of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.
Ritsumeikan University · JPDaiichi University of Pharmacy · JPKansai Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pruni Cortex is a herbal drug from the bark of the Japanese flowering cherries, Prunus jamasakura or Prunus verecunda, and is included in the traditional Japanese herbal (Kampo) formula Jumihaidokuto, which is administered orally to patients suffering from inflammatory skin diseases. The flavanones contained in Pruni Cortex (e.g., sakuranetin and naringenin) have potent anti-inflammatory, anti-allergic, and anti-microbial activities. Although the effects of Pruni Cortex on skin disease have been well studied, reports regarding its pharmacological effects on the liver are limited. In this study, we extracted the bark of Prunus jamasakura and purified it to isolate the pharmacologically active constituents by monitoring nitric oxide (NO) production in rat hepatocytes that were treated with the pro-inflammatory cytokine, interleukin (IL)-1β. Sakuranetin and (-)-naringenin, which were present in an ethyl acetate-soluble fraction of the bark extract, significantly inhibited NO induction and inducible nitric oxide synthase (iNOS) expression. These two flavanones decreased the expression of type 1 IL-1 receptor gene and phosphorylation of Akt, also known as protein kinase B, which is regulated by phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K). Furthermore, sakuranetin decreased the phosphorylation of the activator isoforms of CCAAT/enhancer-binding protein β (C/EBPβ), which synergistically activates the transcription of the iNOS gene with nuclear factor κB (NF-κB). Therefore, sakuranetin inhibited the co-activating activity of C/EBPβ with NF-κB, leading to the suppression of iNOS gene expression in hepatocytes. Taken together, sakuranetin in Pruni Cortex downregulated the iNOS gene by inhibiting PI3K/Akt signal transduction and the phosphorylation of C/EBPβ. These results imply that sakuranetin may be primarily responsible for the anti-inflammatory effects of Pruni Cortex in the liver.

Indexed as

AnimalsCCAAT-Enhancer-Binding Protein-betaCytokinesDown-RegulationFlavanonesFlavonoidsHepatocytesHumansInterleukin-1betaLiverMaleMedicine, KampoNF-kappa BNitric OxideNitric Oxide Synthase Type IIPhosphoinositide-3 Kinase InhibitorsCCAAT-Enhancer-Binding Protein-betaCytokinesFlavanonesFlavonoidsInterleukin-1betajumi-haidoku-tonaringeninNF-kappa BNitric OxideNitric Oxide Synthase Type IINOS2 protein, humanPhosphoinositide-3 Kinase InhibitorsPhytoalexinsPlant ExtractsProto-Oncogene Proteins c-aktReceptors, Interleukin-1sakuranetinCCAAT/enhancer-binding protein βCherry barkInterleukin 1 receptorKampo medicineNitric oxideNuclear factor κB

Identifiers

PMID30467676
OpenAlexW2901672036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.